Table 1.
Baseline clinical characteristics
| MPOlow (n = 15) | Control (n = 30) | P-value | |
|---|---|---|---|
| Age, years | 56 ± 14.7 | 56 ± 15.8 | 0.887 |
| Gender (male), % | 40.0 | 40.0 | 0.629 |
| BMI, kg/m2 | 24.7 ± 4.2 | 23.5 ± 3.4 | 0.284 |
| Hypertension, % | 46.7 | 46.7 | 0.623 |
| Hyperlipoproteinaemia, % | 26.7 | 26.7 | 0.632 |
| Diabetes mellitus, % | 20.0 | 20.0 | 0.644 |
| Current smoking, % | 20.0 | 20.0 | 0.644 |
| ASA, % | 20.0 | 26.7 | 0.460 |
| Clopidogrel, % | 6.7 | 6.7 | 0.714 |
| Beta-blockers, % | 46.7 | 33.3 | 0.292 |
| ACE-Inhibitors, % | 20.0 | 26.7 | 0.460 |
| CSE inhibitor,% | 26.7 | 23.3 | 0.540 |
| Haemoglobin, g/dL | 13.0 ± 1.1 | 13.6 ± 1.4 | 0.226 |
| Leucocytes, 10e6/mL | 7.48 ± 4.65 | 6.55 ± 2.25 | 0.375 |
| Creatinine, mg/dL | 1.06 ± 0.44 | 1.04 ± 0.64 | 0.914 |
| C-reactive protein, mg/dL | 0.87 ± 2.29 | 1.11 ± 2.68 | 0.762 |
| Total cholesterol, mg/dL | 171.4 ± 42.0 | 186.7 ± 48.1 | 0.302 |
| LDL, mg/dL | 86.7 ± 27.2 | 102.0 ± 34.6 | 0.144 |
| HDL, mg/dL | 63.7 ± 13.9 | 62.3 ± 19.1 | 0.811 |
| Triglycerides, mg/dL | 134.3 ± 78.7 | 111.7 ± 71.4 | 0.338 |
| RRsys, mmHg | 130 ± 21 | 140 ± 30 | 0.371 |
| RRdia, mmHg | 77 ± 15 | 77 ± 12 | 0.900 |
| Heart rate, b.p.m. | 68 ± 11 | 69 ± 10 | 0.830 |
BMI, body mass index; ASA, acetyl salicylic acid; ACE, angiotensin-converting enzyme, CSE, cholesterol synthase; MPO, myeloperoxidase. Mean ± SD.